Comparison of Anti-Xa and Dilute Russell Viper Venom Time Assays in Quantifying Drug Levels in Patients on Therapeutic Doses of Rivaroxaban

被引:42
作者
Gosselin, Robert C. [1 ]
Funk, Dorothy M. [2 ]
Taylor, J. Michael [2 ]
Francart, Suzanne J. [3 ]
Hawes, Emily M. [3 ,4 ]
Friedman, Kenneth D. [6 ]
Moll, Stephan [3 ,5 ]
机构
[1] Calif State Univ Sacramento, Davis Hlth Syst, Dept Pathol & Lab Med, Sacramento, CA 95819 USA
[2] Corp Amer Holdings, Colorado Coagulat, Englewood, CO 80112 USA
[3] Univ N Carolina, Dept Pharm, Chapel Hill, NC USA
[4] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27514 USA
[5] Univ N Carolina, Hemophilia & Thrombosis Ctr, Chapel Hill, NC 27514 USA
[6] Blood Ctr Wisconsin, Hemostasis Reference Lab, Milwaukee, WI USA
关键词
PROTHROMBIN TIME; ORAL RIVAROXABAN; PLASMA; THROMBOPROPHYLAXIS; PERFORMANCE; HEPARIN; TESTS;
D O I
10.5858/arpa.2013-0750-OA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Rivaroxaban is a new oral anticoagulant that functions as a direct anti-Xa inhibitor. Although routine monitoring is not required, measurement of plasma concentrations may be necessary in certain clinical situations. Routine coagulation assays, such as the prothrombin time and, to a lesser degree, activated partial thromboplastin time, correlate with drug concentration, but because of reagent variability, these methods are not reliable for determining rivaroxaban anticoagulation. Objective.-To compare different methods and calibrators for measuring rivaroxaban, including the chromogenic anti-Xa assay, which, when calibrated with a rivaroxaban standard, may be more appropriate for determining anticoagulation. Design.-We compared measured rivaroxaban concentrations with the same anti-Xa kit but used different calibrators, with different anti-Xa kits but the same calibrators, with antithrombin-supplemented anti-Xa kit versus nonsupplemented kits, and with 2 methods based on rivaroxaban-calibrated, high-phospholipid, dilute Russell viper venom time. Regression and paired t test statistics were used to determine correlation and significant differences among methods and calibrator sources. Results.-Although there was strong correlation, statistically significant biases existed among methods that report rivaroxaban levels. A single-source calibrator did not alleviate those differences among methods. High-phospholipid Russell viper venom reagents correlated with rivaroxaban concentration but were not better than chromogenic anti-Xa methods. Conclusions.-Rivaroxaban-calibrated, anti-Xa measurements correlate well, but the clinical significance of the variation with rivaroxaban measurements is uncertain. The antithrombin-supplemented, anti-Xa method should be avoided for measuring rivaroxaban.
引用
收藏
页码:1680 / 1684
页数:5
相关论文
共 18 条
[11]   Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay [J].
Kitchen, S ;
Theaker, J ;
Preston, FE .
BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (02) :137-144
[12]   Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin [J].
Mani, Helen ;
Rohde, Gabriele ;
Stratmann, Gertrud ;
Hesse, Christian ;
Herth, Natalie ;
Schwers, Stephan ;
Perzborn, Elisabeth ;
Lindhoff-Last, Edelgard .
THROMBOSIS AND HAEMOSTASIS, 2012, 108 (01) :191-198
[13]   Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time [J].
Mani, Helen ;
Hesse, Christian ;
Stratmann, Gertrud ;
Lindhoff-Last, Edelgard .
THROMBOSIS AND HAEMOSTASIS, 2011, 106 (01) :156-164
[14]   Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction Results From the ATLAS ACS-2-TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51) [J].
Mega, Jessica L. ;
Braunwald, Eugene ;
Murphy, Sabina A. ;
Plotnikov, Alexei N. ;
Burton, Paul ;
Kiss, Robert Gabor ;
Parkhomenko, Alexander ;
Tendera, Michal ;
Widimsky, Petr ;
Gibson, C. Michael .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (18) :1853-1859
[15]   Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation [J].
Patel, Manesh R. ;
Mahaffey, Kenneth W. ;
Garg, Jyotsna ;
Pan, Guohua ;
Singer, Daniel E. ;
Hacke, Werner ;
Breithardt, Guenter ;
Halperin, Jonathan L. ;
Hankey, Graeme J. ;
Piccini, Jonathan P. ;
Becker, Richard C. ;
Nessel, Christopher C. ;
Paolini, John F. ;
Berkowitz, Scott D. ;
Fox, Keith A. A. ;
Califf, Robert M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (10) :883-891
[16]   Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry [J].
Rohde, G. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 872 (1-2) :43-50
[17]   Evaluation of the Prothrombin Time for Measuring Rivaroxaban Plasma Concentrations Using Calibrators and Controls: Results of a Multicenter Field Trial [J].
Samama, Meyer Michel ;
Contant, Genevieve ;
Spiro, Theodore E. ;
Perzborn, Elisabeth ;
Le Flem, Lena ;
Guinet, Celine ;
Gourmelin, Yves ;
Martinoli, Jean Luc .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2012, 18 (02) :150-158
[18]   Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor [J].
Samama, Meyer Michel ;
Martinoli, Jean-Luc ;
LeFlem, Lena ;
Guinet, Celine ;
Plu-Bureau, Genevieve ;
Depasse, Francois ;
Perzborn, Elisabeth .
THROMBOSIS AND HAEMOSTASIS, 2010, 103 (04) :815-825